BACKGROUND AND OBJECTIVES: In clinical practice, antiretroviral regimens are often interrupted or modified for intolerance and toxicity. The objective of this study was to develop an in vitro to in vivo extrapolation (IVIVE) approach to describe the interaction when efavirenz is switched to either maraviroc or nevirapine and to test different switching scenarios to identify the best strategy. METHODS: In vitro data describing the chemical and absorption, tissue distribution, metabolism and excretion (ADME) characteristics of efavirenz, maraviroc and nevirapine were obtained from the literature, and used to simulate plasma exposures of these drugs using the Simcyp Population-Based Simulator. The predicted maraviroc and nevirapine exposures were compared with data from clinical studies evaluating their exposures following a switch from efavirenz. RESULTS: Model predictions for maraviroc and nevirapine exposure were in agreement with observed data. The simulations suggest that the waning efavirenz induction effect following discontinuation necessitated increasing maraviroc to 600 mg twice daily for 1 week after efavirenz cessation. Alternatively, adequate exposure of maraviroc was shown with a dose of 450 mg for 2 weeks. Efavirenz waning induction did not affect nevirapine exposure. CONCLUSION: IVIVE modelling successfully predicted patient drug exposure. This modelling technique is able to inform the design of clinical studies, and allows assessment of pragmatic dosing strategies under complex therapeutic scenarios.
BACKGROUND AND OBJECTIVES: In clinical practice, antiretroviral regimens are often interrupted or modified for intolerance and toxicity. The objective of this study was to develop an in vitro to in vivo extrapolation (IVIVE) approach to describe the interaction when efavirenz is switched to either maraviroc or nevirapine and to test different switching scenarios to identify the best strategy. METHODS: In vitro data describing the chemical and absorption, tissue distribution, metabolism and excretion (ADME) characteristics of efavirenz, maraviroc and nevirapine were obtained from the literature, and used to simulate plasma exposures of these drugs using the Simcyp Population-Based Simulator. The predicted maraviroc and nevirapine exposures were compared with data from clinical studies evaluating their exposures following a switch from efavirenz. RESULTS: Model predictions for maraviroc and nevirapine exposure were in agreement with observed data. The simulations suggest that the waning efavirenz induction effect following discontinuation necessitated increasing maraviroc to 600 mg twice daily for 1 week after efavirenz cessation. Alternatively, adequate exposure of maraviroc was shown with a dose of 450 mg for 2 weeks. Efavirenz waning induction did not affect nevirapine exposure. CONCLUSION: IVIVE modelling successfully predicted patient drug exposure. This modelling technique is able to inform the design of clinical studies, and allows assessment of pragmatic dosing strategies under complex therapeutic scenarios.
Authors: M J Lamson; J P Sabo; T R MacGregor; J W Pav; L Rowland; A Hawi; M Cappola; P Robinson Journal: Biopharm Drug Dispos Date: 1999-09 Impact factor: 1.627
Authors: Andrew Scourfield; Jiexin Zheng; Suchitra Chinthapalli; Laura Waters; Thomas Martin; Sundhiya Mandalia; Mark Nelson Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: Jeffrey T Schouten; Amy Krambrink; Heather J Ribaudo; Anne Kmack; Nancy Webb; Cecilia Shikuma; Daniel R Kuritzkes; Roy M Gulick Journal: Clin Infect Dis Date: 2010-03-01 Impact factor: 9.079
Authors: Chinyere Okoli; Marco Siccardi; Sathish Thomas-William; Ngozi Dufty; Kirstin Khonyongwa; Jonathan Ainsworth; John Watson; Roseanne Cook; Kate Gandhi; Geraldine Hickinbottom; Andrew Owen; Stephen Taylor Journal: J Antimicrob Chemother Date: 2011-12-15 Impact factor: 5.790
Authors: Alessandro Schipani; Christoph Wyen; Tabitha Mahungu; Heidy Hendra; Deirdre Egan; Marco Siccardi; Gerry Davies; Saye Khoo; Gerd Fätkenheuer; Michael Youle; Jürgen Rockstroh; Norbert H Brockmeyer; Margaret A Johnson; Andrew Owen; David J Back Journal: J Antimicrob Chemother Date: 2011-03-25 Impact factor: 5.790